CL2014001966A1 - Formulación seca en polvo que comprende a)una fracción de partículas finas, b)una fraccion de particulas gruesas y c) dihidrato del fumarato de formoterol en combinacion con dipropionato de beclometasona, como ingredientes activos; inhalador de polvo seco; uso en la prevencion y/o el tratamiento de asma o enfermedad pulmonar obstructiva crónica. - Google Patents

Formulación seca en polvo que comprende a)una fracción de partículas finas, b)una fraccion de particulas gruesas y c) dihidrato del fumarato de formoterol en combinacion con dipropionato de beclometasona, como ingredientes activos; inhalador de polvo seco; uso en la prevencion y/o el tratamiento de asma o enfermedad pulmonar obstructiva crónica.

Info

Publication number: CL2014001966A1
Authority: CL; Chile
Prior art keywords: fraction; dry powder; dihydrate; asthma; prevention
Prior art date: 2012-01-25

Application number

CL2014001966A

Other languages

English (en)

Inventor

Elisa Monari

Anna Maria Cantarelli

Daniela Cocconi

Irene Pasquali

Original Assignee

Chiesi Farma Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-01-25

Filing date

2014-07-24

Publication date

2014-11-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47715987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001966(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-07-24 Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa

2014-11-14 Publication of CL2014001966A1 publication Critical patent/CL2014001966A1/es

Links

OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 title 1
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 title 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title 1
239000004480 active ingredient Substances 0.000 title 1
208000006673 asthma Diseases 0.000 title 1
229950000210 beclometasone dipropionate Drugs 0.000 title 1
239000011362 coarse particle Substances 0.000 title 1
150000004683 dihydrates Chemical class 0.000 title 1
229940112141 dry powder inhaler Drugs 0.000 title 1
239000010419 fine particle Substances 0.000 title 1
229960000193 formoterol fumarate Drugs 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000000843 powder Substances 0.000 title 1
230000002265 prevention Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Otolaryngology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL2014001966A 2012-01-25 2014-07-24 Formulación seca en polvo que comprende a)una fracción de partículas finas, b)una fraccion de particulas gruesas y c) dihidrato del fumarato de formoterol en combinacion con dipropionato de beclometasona, como ingredientes activos; inhalador de polvo seco; uso en la prevencion y/o el tratamiento de asma o enfermedad pulmonar obstructiva crónica. CL2014001966A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP12152392		2012-01-25

Publications (1)

Publication Number	Publication Date
CL2014001966A1 true CL2014001966A1 (es)	2014-11-14

Family

ID=47715987

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014001966A CL2014001966A1 (es)	2012-01-25	2014-07-24	Formulación seca en polvo que comprende a)una fracción de partículas finas, b)una fraccion de particulas gruesas y c) dihidrato del fumarato de formoterol en combinacion con dipropionato de beclometasona, como ingredientes activos; inhalador de polvo seco; uso en la prevencion y/o el tratamiento de asma o enfermedad pulmonar obstructiva crónica.

Country Status (37)

Country	Link
US (3)	US10028964B2 (es)
EP (7)	EP3527196B1 (es)
JP (1)	JP6104282B2 (es)
KR (3)	KR101895279B1 (es)
CN (2)	CN104080444B (es)
AR (1)	AR089805A1 (es)
AU (1)	AU2013211656B2 (es)
BR (1)	BR112014017481A8 (es)
CA (1)	CA2862548C (es)
CL (1)	CL2014001966A1 (es)
CO (1)	CO7010836A2 (es)
CY (1)	CY1120684T1 (es)
DK (6)	DK3527199T3 (es)
EA (2)	EA026267B1 (es)
ES (6)	ES2929807T3 (es)
FI (2)	FI3527198T3 (es)
GE (1)	GEP201706767B (es)
HR (6)	HRP20230147T1 (es)
HU (6)	HUE040525T2 (es)
IL (1)	IL233784A0 (es)
LT (5)	LT3412277T (es)
MA (1)	MA35859B1 (es)
MX (2)	MX368199B (es)
MY (1)	MY165888A (es)
NZ (1)	NZ627837A (es)
PE (1)	PE20141703A1 (es)
PH (1)	PH12014501565B1 (es)
PL (6)	PL3527196T3 (es)
PT (6)	PT3527196T (es)
RS (5)	RS63761B1 (es)
SG (1)	SG11201404350PA (es)
SI (3)	SI2806855T1 (es)
TN (1)	TN2014000322A1 (es)
TW (1)	TWI559940B (es)
UA (1)	UA115543C2 (es)
WO (1)	WO2013110632A1 (es)
ZA (1)	ZA201405464B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3527199T3 (da) *	2012-01-25	2022-10-24	Chiesi Farm Spa	Tørpulverformulering omfattende et kortikosteroid og et beta-adrenergikum til indgivelse via inhalation
KR102275904B1 (ko)	2013-07-11	2021-07-13	키에시 파르마슈티시 엣스. 피. 에이.	흡입에 의한 투여를 위한 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제
UA118861C2 (uk) *	2013-12-06	2019-03-25	Оріон Корпорейшн	Спосіб отримання сухих порошкових композицій для інгаляцій
JP6919093B2 (ja)	2014-10-08	2021-08-18	ザンボンソシエタペルアチオニ	配合物の安定性を高めるために噴霧乾燥によって得られる少なくとも１種の乾燥粉末を含む組成物
CN109789107B (zh) *	2016-09-29	2021-12-03	广东东阳光药业有限公司	药物组合物
EP3621590B1 (en) *	2017-05-11	2021-09-01	Chiesi Farmaceutici S.p.A.	A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
EP3687500A1 (en)	2017-09-29	2020-08-05	Crititech, Inc.	Glucocorticoid particles and their use
EP3833964B1 (en)	2018-08-07	2023-07-26	Norton (Waterford) Limited	Application of raman spectroscopy for the manufacture of inhalation powders
JP7368065B2 (ja)	2018-10-30	2023-10-24	キエージィファーマチェウティチエス．ペー．アー．	人工呼吸器を装着している患者に薬物を投与するための装置
KR102898819B1 (ko)	2019-09-24	2025-12-12	키에시 파르마슈티시 엣스. 피. 에이.	흡입용 건조 분말 제제를 위한 신규 담체 입자
US20240033222A1 (en)	2020-08-14	2024-02-01	Norton (Waterford) Limited	An inhalable formulation of fluticasone propionate and albuterol sulfate
US20250050042A1 (en) *	2021-12-21	2025-02-13	Chiesi Farmaceutici S.P.A.	Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9501841D0 (en) *	1995-01-31	1995-03-22	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
CA2347856C (en) *	1998-11-13	2009-02-17	Jagotec Ag	Dry powder for inhalation
IT1309592B1 (it) *	1999-03-05	2002-01-24	Chiesi Farma Spa	Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
PE20011227A1 (es)	2000-04-17	2002-01-07	Chiesi Farma Spa	Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en)	2000-06-21	2000-08-09	Glaxo Group Ltd	Medicament dispenser
FI20002215A0 (fi) *	2000-10-06	2000-10-06	Orion Yhtymae Oyj	Yhdistelmäpartikkelit
PT1386630E (pt)	2002-07-31	2006-09-29	Chiesi Farma Spa	Inalador em po
JO3102B1 (ar) *	2004-03-17	2017-09-20	Chiesi Framaceutici S P A	صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
ES2257152B1 (es) *	2004-05-31	2007-07-01	Laboratorios Almirall S.A.	Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1944018A1 (en) *	2007-01-10	2008-07-16	CHIESI FARMACEUTICI S.p.A.	Micronised particles of low-dosage strength active agents for powder formulations for inhalation
EP1982709A1 (en) *	2007-04-19	2008-10-22	CHIESI FARMACEUTICI S.p.A.	Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
WO2010097188A1 (en) *	2009-02-25	2010-09-02	Chiesi Farmaceutici S.P.A.	Inhalation particles comprising a salt of carmoterol and a corticosteroid
JP2012526726A (ja) *	2009-05-15	2012-11-01	株式会社新日本科学	薬物動態が改善された鼻腔内用薬学的組成物
GB0914240D0 (en)	2009-08-14	2009-09-30	Breath Ltd	Steroid solvates
RU2650175C2 (ru) *	2009-10-02	2018-04-10	КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.	Фармацевтические аэрозольные препараты формотерола и беклометазона дипропионата
BR112012024059B1 (pt) *	2010-04-01	2021-06-01	Chiesi Farmaceutici S.P.A.	Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco
DK2560611T3 (en)	2010-04-21	2018-02-26	Chiesi Farm Spa	Process for providing particles with reduced electrostatic charges
DK3527199T3 (da) *	2012-01-25	2022-10-24	Chiesi Farm Spa	Tørpulverformulering omfattende et kortikosteroid og et beta-adrenergikum til indgivelse via inhalation
KR102275904B1 (ko) *	2013-07-11	2021-07-13	키에시 파르마슈티시 엣스. 피. 에이.	흡입에 의한 투여를 위한 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제

2013
- 2013-01-23 DK DK19167839.0T patent/DK3527199T3/da active
- 2013-01-23 EP EP19167775.6A patent/EP3527196B1/en active Active
- 2013-01-23 HR HRP20230147TT patent/HRP20230147T1/hr unknown
- 2013-01-23 LT LTEP18181331.2T patent/LT3412277T/lt unknown
- 2013-01-23 RS RS20221007A patent/RS63761B1/sr unknown
- 2013-01-23 PT PT191677756T patent/PT3527196T/pt unknown
- 2013-01-23 ES ES19167839T patent/ES2929807T3/es active Active
- 2013-01-23 SI SI201331186T patent/SI2806855T1/sl unknown
- 2013-01-23 MY MYPI2014002176A patent/MY165888A/en unknown
- 2013-01-23 ES ES19167829T patent/ES2929137T3/es active Active
- 2013-01-23 SI SI201332032T patent/SI3412277T1/sl unknown
- 2013-01-23 PT PT191678390T patent/PT3527199T/pt unknown
- 2013-01-23 HR HRP20221433TT patent/HRP20221433T1/hr unknown
- 2013-01-23 HR HRP20181550TT patent/HRP20181550T1/hr unknown
- 2013-01-23 SI SI201332092T patent/SI3527198T1/sl unknown
- 2013-01-23 WO PCT/EP2013/051187 patent/WO2013110632A1/en not_active Ceased
- 2013-01-23 EP EP18181331.2A patent/EP3412277B1/en active Active
- 2013-01-23 SG SG11201404350PA patent/SG11201404350PA/en unknown
- 2013-01-23 CN CN201380006645.XA patent/CN104080444B/zh active Active
- 2013-01-23 BR BR112014017481A patent/BR112014017481A8/pt not_active Application Discontinuation
- 2013-01-23 CN CN201610080909.1A patent/CN105726548B/zh active Active
- 2013-01-23 EP EP13704372.5A patent/EP2806855B1/en active Active
- 2013-01-23 HR HRP20221432TT patent/HRP20221432T1/hr unknown
- 2013-01-23 EP EP19167839.0A patent/EP3527199B1/en active Active
- 2013-01-23 KR KR1020177027831A patent/KR101895279B1/ko active Active
- 2013-01-23 PL PL19167775.6T patent/PL3527196T3/pl unknown
- 2013-01-23 AU AU2013211656A patent/AU2013211656B2/en active Active
- 2013-01-23 HU HUE13704372A patent/HUE040525T2/hu unknown
- 2013-01-23 DK DK18181331.2T patent/DK3412277T3/da active
- 2013-01-23 HU HUE19167829A patent/HUE060421T2/hu unknown
- 2013-01-23 HU HUE19167839A patent/HUE060705T2/hu unknown
- 2013-01-23 ES ES19167835T patent/ES2996893T3/es active Active
- 2013-01-23 EA EA201491281A patent/EA026267B1/ru unknown
- 2013-01-23 PT PT137043725T patent/PT2806855T/pt unknown
- 2013-01-23 US US14/417,484 patent/US10028964B2/en active Active
- 2013-01-23 LT LTEP19167839.0T patent/LT3527199T/lt unknown
- 2013-01-23 HU HUE18181331A patent/HUE061566T2/hu unknown
- 2013-01-23 PL PL19167839.0T patent/PL3527199T3/pl unknown
- 2013-01-23 PL PL13704372T patent/PL2806855T3/pl unknown
- 2013-01-23 DK DK19167835.8T patent/DK3527198T3/da active
- 2013-01-23 RS RS20221033A patent/RS63759B1/sr unknown
- 2013-01-23 GE GEAP201313532A patent/GEP201706767B/en unknown
- 2013-01-23 ES ES19167775T patent/ES2928688T3/es active Active
- 2013-01-23 JP JP2014553692A patent/JP6104282B2/ja active Active
- 2013-01-23 EA EA201690187A patent/EA031566B1/ru unknown
- 2013-01-23 CA CA2862548A patent/CA2862548C/en active Active
- 2013-01-23 RS RS20220971A patent/RS63706B1/sr unknown
- 2013-01-23 DK DK19167829.1T patent/DK3527197T3/da active
- 2013-01-23 PL PL19167835.8T patent/PL3527198T3/pl unknown
- 2013-01-23 PT PT191678291T patent/PT3527197T/pt unknown
- 2013-01-23 RS RS20230066A patent/RS63952B1/sr unknown
- 2013-01-23 RS RS20181038A patent/RS57637B1/sr unknown
- 2013-01-23 LT LTEP19167775.6T patent/LT3527196T/lt unknown
- 2013-01-23 UA UAA201408448A patent/UA115543C2/uk unknown
- 2013-01-23 MX MX2016001311A patent/MX368199B/es unknown
- 2013-01-23 EP EP19167829.1A patent/EP3527197B1/en active Active
- 2013-01-23 FI FIEP19167835.8T patent/FI3527198T3/fi active
- 2013-01-23 PL PL18181331.2T patent/PL3412277T3/pl unknown
- 2013-01-23 MX MX2014008631A patent/MX355729B/es active IP Right Grant
- 2013-01-23 PT PT191678358T patent/PT3527198T/pt unknown
- 2013-01-23 HU HUE19167775A patent/HUE060402T2/hu unknown
- 2013-01-23 HU HUE19167835A patent/HUE069624T2/hu unknown
- 2013-01-23 KR KR1020147019763A patent/KR101560288B1/ko active Active
- 2013-01-23 PE PE2014001166A patent/PE20141703A1/es active IP Right Grant
- 2013-01-23 HR HRP20241638TT patent/HRP20241638T1/hr unknown
- 2013-01-23 ES ES13704372.5T patent/ES2683254T3/es active Active
- 2013-01-23 HR HRP20221431TT patent/HRP20221431T1/hr unknown
- 2013-01-23 LT LTEP19167829.1T patent/LT3527197T/lt unknown
- 2013-01-23 EP EP15202117.6A patent/EP3020394A1/en not_active Withdrawn
- 2013-01-23 NZ NZ627837A patent/NZ627837A/en unknown
- 2013-01-23 LT LTEP13704372.5T patent/LT2806855T/lt unknown
- 2013-01-23 EP EP19167835.8A patent/EP3527198B1/en active Active
- 2013-01-23 KR KR1020157019169A patent/KR101786586B1/ko active Active
- 2013-01-23 PT PT181813312T patent/PT3412277T/pt unknown
- 2013-01-23 DK DK13704372.5T patent/DK2806855T3/en active
- 2013-01-23 ES ES18181331T patent/ES2938466T3/es active Active
- 2013-01-23 PL PL19167829.1T patent/PL3527197T3/pl unknown
- 2013-01-23 DK DK19167775.6T patent/DK3527196T3/da active
- 2013-01-23 FI FIEP18181331.2T patent/FI3412277T3/fi active
- 2013-01-24 AR ARP130100225A patent/AR089805A1/es not_active Application Discontinuation
- 2013-01-24 US US13/748,882 patent/US8778402B2/en active Active
- 2013-01-24 TW TW102102606A patent/TWI559940B/zh active
2014
- 2014-07-07 PH PH12014501565A patent/PH12014501565B1/en unknown
- 2014-07-11 MA MA37200A patent/MA35859B1/fr unknown
- 2014-07-24 TN TNP2014000322A patent/TN2014000322A1/fr unknown
- 2014-07-24 CL CL2014001966A patent/CL2014001966A1/es unknown
- 2014-07-24 CO CO14161092A patent/CO7010836A2/es unknown
- 2014-07-24 ZA ZA2014/05464A patent/ZA201405464B/en unknown
- 2014-07-24 IL IL233784A patent/IL233784A0/en active IP Right Grant
2018
- 2018-06-22 US US16/015,666 patent/US10946029B2/en active Active
- 2018-09-11 CY CY181100948T patent/CY1120684T1/el unknown

Also Published As

Publication number	Publication date
LT3527197T (lt)	2022-11-25
HUE061566T2 (hu)	2023-07-28
HUE040525T2 (hu)	2019-03-28
PT2806855T (pt)	2018-09-28
ES2996893T3 (en)	2025-02-13
EA026267B1 (ru)	2017-03-31
PE20141703A1 (es)	2014-11-24
DK2806855T3 (en)	2018-09-03
EP3527196A1 (en)	2019-08-21
GEP201706767B (en)	2017-11-10
PL2806855T3 (pl)	2018-12-31
KR101895279B1 (ko)	2018-09-05
KR101560288B1 (ko)	2015-10-14
US20150164915A1 (en)	2015-06-18
AU2013211656B2 (en)	2017-07-13
RS63706B1 (sr)	2022-11-30
TN2014000322A1 (en)	2015-12-21
MY165888A (en)	2018-05-18
PH12014501565A1 (en)	2014-10-08
SI3412277T1 (sl)	2023-03-31
FI3412277T3 (fi)	2023-03-23
HUE060705T2 (hu)	2023-04-28
ZA201405464B (en)	2015-12-23
HRP20181550T1 (hr)	2018-11-30
CO7010836A2 (es)	2014-07-31
EA031566B1 (ru)	2019-01-31
FI3527198T3 (fi)	2024-12-13
JP6104282B2 (ja)	2017-03-29
US8778402B2 (en)	2014-07-15
EP3020394A1 (en)	2016-05-18
RS63952B1 (sr)	2023-02-28
MX355729B (es)	2018-04-27
HUE060402T2 (hu)	2023-02-28
HRP20221433T1 (hr)	2023-01-06
SG11201404350PA (en)	2014-08-28
AR089805A1 (es)	2014-09-17
ES2683254T3 (es)	2018-09-25
ES2928688T3 (es)	2022-11-22
MX368199B (es)	2019-09-24
HRP20241638T1 (hr)	2025-02-14
RS63761B1 (sr)	2022-12-30
PL3527199T3 (pl)	2022-12-12
EP3412277B1 (en)	2022-12-14
JP2015508416A (ja)	2015-03-19
KR20150089093A (ko)	2015-08-04
DK3412277T3 (da)	2023-02-20
PL3527196T3 (pl)	2022-11-21
PH12014501565B1 (en)	2014-10-08
PT3412277T (pt)	2023-02-14
RS63759B1 (sr)	2022-12-30
US10028964B2 (en)	2018-07-24
EP3527199B1 (en)	2022-09-07
MA35859B1 (fr)	2014-12-01
KR20140114374A (ko)	2014-09-26
LT3527196T (lt)	2022-11-25
CN105726548A (zh)	2016-07-06
EP3527198B1 (en)	2024-10-09
EA201491281A1 (ru)	2014-12-30
MX2014008631A (es)	2014-08-21
DK3527199T3 (da)	2022-10-24
PL3412277T3 (pl)	2023-06-19
DK3527196T3 (da)	2022-10-24
BR112014017481A2 (pt)	2017-06-13
KR101786586B1 (ko)	2017-10-18
CY1120684T1 (el)	2019-12-11
EP3527197B1 (en)	2022-09-07
KR20170116234A (ko)	2017-10-18
EP3527198A1 (en)	2019-08-21
PL3527198T3 (pl)	2025-01-27
SI2806855T1 (sl)	2018-11-30
AU2013211656A1 (en)	2014-07-24
SI3527198T1 (sl)	2025-03-31
HUE060421T2 (hu)	2023-02-28
PL3527197T3 (pl)	2022-11-21
CA2862548C (en)	2020-07-07
PT3527196T (pt)	2022-10-18
ES2929137T3 (es)	2022-11-25
NZ627837A (en)	2016-04-29
US20130189324A1 (en)	2013-07-25
TW201334810A (zh)	2013-09-01
ES2929807T3 (es)	2022-12-01
HK1200021A1 (en)	2015-07-31
DK3527198T3 (da)	2024-10-28
WO2013110632A1 (en)	2013-08-01
EP3527196B1 (en)	2022-09-07
EP2806855A1 (en)	2014-12-03
BR112014017481A8 (pt)	2021-06-15
UA115543C2 (uk)	2017-11-27
EP2806855B1 (en)	2018-07-11
RS57637B1 (sr)	2018-11-30
ES2938466T3 (es)	2023-04-11
CA2862548A1 (en)	2013-08-01
TWI559940B (en)	2016-12-01
IL233784A0 (en)	2014-09-30
EP3527199A1 (en)	2019-08-21
LT2806855T (lt)	2018-10-10
HUE069624T2 (hu)	2025-03-28
PT3527198T (pt)	2024-12-04
HRP20221431T1 (hr)	2023-01-06
US10946029B2 (en)	2021-03-16
LT3527199T (lt)	2022-12-12
EA201690187A1 (ru)	2016-05-31
HRP20230147T1 (hr)	2023-03-31
PT3527197T (pt)	2022-10-26
LT3412277T (lt)	2023-04-25
US20180296573A1 (en)	2018-10-18
PT3527199T (pt)	2022-11-08
EP3412277A1 (en)	2018-12-12
DK3527197T3 (da)	2022-10-24
HRP20221432T1 (hr)	2023-01-06
CN104080444B (zh)	2017-06-20
CN105726548B (zh)	2019-05-14
EP3527197A1 (en)	2019-08-21
CN104080444A (zh)	2014-10-01

Publication	Publication Date	Title
CL2014001966A1 (es)	2014-11-14	Formulación seca en polvo que comprende a)una fracción de partículas finas, b)una fraccion de particulas gruesas y c) dihidrato del fumarato de formoterol en combinacion con dipropionato de beclometasona, como ingredientes activos; inhalador de polvo seco; uso en la prevencion y/o el tratamiento de asma o enfermedad pulmonar obstructiva crónica.
CL2014003286A1 (es)	2015-02-20	Composicion farmaceutica en forma de polvo seco que comprende abediterol; y su uso para el tratamiento de una enfermedad respiratoria seleccionada de asma y enfermedad pulmonar obstructiva cronica.
CL2011000696A1 (es)	2011-07-29	Particulas inhalables que comprenden una forma anhidra amorfa de tiotropio con un agente estabilizante que es lactosa; composicion farmaceutica; procedimiento para prepararlas que incluye secado por atomizacion; y su uso en asma y epoc
PL2941263T3 (pl)	2019-08-30	Oczyszczony wyciąg wyizolowany z pseudolysimachion rotundum var. subintegrum zawierający liczne składniki czynne, wytwarzanie tego ekstraktu i kompozycja zawierająca ekstrakt jako składnik czynny do zapobiegania lub leczenia zapalenia, alergii i astmy
GT201400182A (es)	2015-09-17	Formulaciones farmacéuticas novedosas
CL2016000735A1 (es)	2016-11-11	Inhalador de polvo seco que comprende una composición farmacéutica inhalable que comprende propionato de fluticasona, xinafoato de salmeterol y un vehículo de lactosa; uso para tratar asma o epoc.
TR201000680A2 (tr)	2011-08-22	Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
CL2013000293A1 (es)	2013-05-03	Una formulacion en polvo seco inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto inhibidor de fosfodiesterasa-4, como enantiomero (-) y particulas de un vehiculo; inhalador de polvo seco y envase que comprende a la formulacion, util para la prevencion y/o el tratamiento del asma y epoc.
CL2012003450A1 (es)	2013-03-15	Una formulacion en polvo seca inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto antimuscarinico derivado de 1-azonia-biciclo[2.2.2]octano y particulas de un vehiculo; inhalador de polvo seco que la comprende, util para la prevencion y/o el tratamiento de una enfermedad respiratoria tal como asma y epoc.
PE20141036A1 (es)	2014-08-27	Nueva dosificacion y formulacion
GT201500218A (es)	2017-09-21	Compuesto
TR201000681A2 (tr)	2011-08-22	İnhalasyon yoluyla alınan kuru toz formülasyonları.
BR112017023351A2 (pt)	2018-07-17	composições multidrogas de matriz frágil
MX2015009891A (es)	2016-03-08	Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
WO2011093815A3 (en)	2011-10-20	Pharmaceutical compositions comprising formoterol and mometasone
MX2015014338A (es)	2015-12-07	Composicion farmaceutica que continen budesonida y formoterol.
CL2015002702A1 (es)	2016-08-12	Composiciones farmacéuticas micronizadas.
CL2014003361A1 (es)	2015-05-29	Profarmaco de ácido fosforamidico del compuesto 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida; composicion farmaceutica y uso en el tratamiento o la prevencion de la arritmia.
TR200907913A2 (tr)	2011-05-23	İnhalason yolu ile alınmak üzere kuru toz formunda farmasötik bileşim
BR112015004810A2 (pt)	2017-07-04	preparações de tiotrópio
SG11201507651XA (en)	2015-10-29	Fine dry particulate resveratrol active agent compositions and topical formulations including the same
TR201000730A2 (tr)	2011-08-22	Tiotropyum ve mometazon içeren kuru toz formundaki farmasötik kompozisyon.
TR201004317A2 (tr)	2012-01-23	Türbülans oluşumunu sağlayan inhalasyon cihazı.
TR201000621A2 (tr)	2011-08-22	Tiotropium ve budesonid içeren kuru toz formundaki farmasötik kompozisyon
AR098868A1 (es)	2016-06-22	Composición farmacéutica en polvo seco para inhalación